This combination therapy specifically activates the cGAS-STING signaling pathway and stabilizes the mRNA expression of the chemokine CXCL10 through an EIF4E2-dependent mechanism, thereby promoting T-cell infiltration into the tumor microenvironment and enhancing anti-tumor immune responses (39). The gene discussed is EIF4E2; the disease is neoplasm.